From GLP-1 Medications to BPC-157, CJC-1295 and TB-500, Peptide Therapy Is Generating Enormous Interest. But Promising Science and Regulatory Approval Are Not the Same Thing.

By Samantha Almas | THRIVE With Samantha

I will start with my own perspective. I find peptides fascinating.

I love the science behind them, I am excited by the research taking place in this field, and I believe peptide-based medicine has enormous potential. Some peptides are already established medicines. Others are being investigated for applications ranging from metabolic disease and hormone regulation to tissue repair and healthy aging.

But enthusiasm for the science cannot mean ignoring the questions surrounding it.

In fact, I think the opposite is true.

The more promising an emerging area of medicine becomes, the more important it is to separate what we hope a therapy may eventually do from what has actually been demonstrated in humans, approved by regulators and proven safe at a particular dose for a particular indication.

That distinction has become especially important with peptides.

By 2025, peptides had moved well beyond research laboratories and specialist medical conversations. They were appearing in longevity clinics, wellness discussions, podcasts, social media feeds and online communities. Names such as BPC-157, CJC-1295, ipamorelin, TB-500, GHK-Cu and retatrutide were increasingly familiar to consumers interested in recovery, body composition, healthy aging and performance.

The problem is that these substances do not all occupy the same scientific or regulatory category.

Some peptide-based drugs are approved prescription medicines in Canada. Some compounds have interesting human research but are not approved therapies. Others are supported primarily by animal or laboratory research. Some products sold online have not been authorized by Health Canada at all.

Those differences matter.

First, What Exactly Is a Peptide?

Peptides are short chains of amino acids, which are the same fundamental building blocks used to make proteins. Many peptides occur naturally in the human body and participate in biological signalling.

That is part of what makes peptide therapeutics so interesting.

Rather than thinking about "peptides" as one treatment category, it is more useful to think of them as a broad class of molecules. Different peptides can interact with very different biological systems and have completely different effects.

This is also why saying that peptides are either "good" or "bad" is scientifically unhelpful.

We already use peptide-based medicines in mainstream healthcare.

Insulin is a peptide hormone. GLP-1 receptor agonists are peptide-based therapies. Other peptide medicines are used in endocrinology and additional areas of medicine.

The controversy is therefore not really about whether peptide medicines can work.

They clearly can.

The controversy begins when promising investigational peptides move from laboratories and clinical research into consumer wellness before the evidence and regulatory approvals have caught up.

The Peptides That Are Legal in Canada

One of the most important distinctions consumers need to understand is that there is no single legal status called "peptide therapy."

In Canada, an authorized prescription drug has undergone Health Canada's regulatory review for its approved indication and has a Drug Identification Number, or DIN. Prescription peptide drugs are then used under the supervision of qualified healthcare professionals.

Semaglutide is one familiar example of a peptide-based prescription medication. Tirzepatide, which acts on GIP and GLP-1 receptors, is another. Tirzepatide products including Mounjaro were authorized in Canada, and Zepbound entered the Canadian market in July 2025. Health Products Canada

These medications should not be placed in the same category as a vial of BPC-157 or CJC-1295 purchased from an online "research peptide" company.

They may all be discussed under the broad peptide umbrella, but their evidence, manufacturing standards, approved uses and regulatory status can be completely different.

That distinction is fundamental to this entire conversation.

Then There Is BPC-157

Few peptides illustrate the current controversy better than BPC-157.

BPC-157 has attracted enormous attention for its proposed regenerative and tissue-healing properties. Preclinical research has explored effects involving tissue injury, inflammation and other biological processes. A 2025 review described a substantial body of preclinical work while also emphasizing the lack of comprehensive human clinical evidence required for conventional medical approval. PubMed

This is where I understand the excitement.

When you look at promising preclinical science, it is natural to ask whether we could eventually have therapies capable of improving recovery or supporting tissue repair in ways our existing options cannot.

I find that possibility genuinely exciting.

But "promising" is an important word.

A 2025 systematic review of BPC-157 in musculoskeletal medicine found 35 preclinical studies and only one clinical study among the studies meeting its criteria. The authors concluded that the compound showed interesting regenerative effects in preclinical models while human safety and efficacy data remained very limited. PubMed

A tiny 2025 intravenous pilot study involving only two participants reported no adverse effects under the conditions studied. That is interesting early information. It is not remotely the same thing as establishing safety and efficacy across a large patient population. PubMed

That is precisely where we need to become better at discussing emerging science.

We can be excited without pretending the research is further along than it is.

What About CJC-1295 and Ipamorelin?

CJC-1295 and ipamorelin are frequently discussed in longevity and performance communities because of their relationship with growth hormone signalling.

Importantly, these compounds are not entirely devoid of human research.

CJC-1295 was studied in randomized trials involving healthy adults. Researchers reported sustained increases in growth hormone and IGF-1 following administration. PubMed

Ipamorelin has also been studied in human volunteers. Research demonstrated that it could stimulate growth hormone release and characterized aspects of its pharmacokinetics and pharmacodynamics. PubMed

That is scientifically interesting.

But demonstrating that a molecule causes a biological effect is different from proving that routinely giving it to otherwise healthy people for anti-aging, body composition, recovery or "optimization" produces meaningful long-term benefits that outweigh its risks.

Those are different research questions.

As of the period this article was originally published, CJC-1295 and ipamorelin were not Health Canada-approved wellness or anti-aging therapies.

That distinction should be made clearly whenever they are discussed.

TB-500 Raises Another Important Scientific Problem

TB-500 is frequently promoted online for recovery and tissue repair.

The conversation surrounding it illustrates another problem consumers encounter when researching peptides. Evidence for one molecule can sometimes become attached to a related but different compound.

Research exists around thymosin beta-4 and tissue repair. However, that does not automatically establish that products marketed as TB-500 have the same clinical effects in humans.

This sounds like a technical distinction, but it is enormously important.

Consumers may see a long list of scientific references on a website and understandably assume that the product being sold has been extensively studied. Sometimes those studies involve animal models. Sometimes they involve a related molecule. Sometimes they examine a biological mechanism rather than an actual clinical outcome.

"Research exists" and "this treatment has been clinically proven" are not interchangeable statements.

Retatrutide Shows How Quickly Consumer Demand Can Outrun Drug Development

Retatrutide became another major topic in weight-management and metabolic-health conversations.

The science is compelling enough to generate significant attention, but during the period this article was originally published in October 2025, retatrutide was still investigational rather than an approved Canadian prescription therapy.

That created an extraordinary situation.

Consumers were already searching for and, in some cases, being offered versions of a drug that was still undergoing formal clinical development.

This is where the wellness marketplace can become particularly concerning.

Interest in an investigational drug does not magically turn an online version of that drug into an approved pharmaceutical product.

The clinical trial product being studied by a pharmaceutical manufacturer and a vial purchased through an unauthorized website should never automatically be assumed to be equivalent.

"Research Use Only" Does Not Mean Approved for Human Use

This is perhaps one of the most important points in this article.

Consumers increasingly encounter peptide products online carrying language such as "research use only" or "not for human consumption."

That language can create a false sense that the product exists within some regulatory grey area that makes personal use acceptable.

It does not.

Health Canada has specifically warned that this type of labelling does not exempt unauthorized peptide products from regulatory requirements. The agency has seized unauthorized injectable peptide products sold in Canada, including BPC-157, CJC-1295, GHK-Cu, ipamorelin, MOTS-C, retatrutide, TB-500 and others. Recalls Canada

That raises another issue that is sometimes lost in the peptide debate.

Even if a molecule eventually proves effective, what is actually inside the vial still matters.

The Controversy Is Not Only About the Molecule

One of the strongest arguments for caution around unauthorized peptides has nothing to do with whether the underlying science ultimately succeeds.

It is manufacturing.

Approved pharmaceutical products are subject to standards concerning identity, purity, manufacturing, storage and quality.

An unauthorized injectable product purchased online may not provide the same assurances.

Health Canada has warned that unauthorized injectable drugs may contain contaminants or unlisted ingredients, contain too much or too little active ingredient, be improperly manufactured or stored, or create infection and other health risks. Recalls Canada

That creates two completely separate questions.

Does the molecule work?

And:

Do you actually know what is in the vial you are injecting?

A fascinating answer to the first question does not solve the second.

The Peptide Debate: Two Medical Perspectives

The following is a constructed debate, not a transcript of real physicians. I have written it to represent two of the strongest perspectives currently shaping the peptide conversation.

The Physician Urging Caution

Physician: "My concern is not that peptide science lacks promise. My concern is that consumers are confusing biological plausibility with established medicine."

The physician points to BPC-157 as an example. Animal and laboratory research may be interesting, but large, controlled human trials demonstrating safety, effective dosing, long-term outcomes and clear clinical benefit are still lacking.

"For me, the question is not whether something might work. Medicine is full of compounds that looked promising early in development. The question is whether we have enough evidence to know that the expected benefit outweighs the potential risk for the patient sitting in front of me."

The physician is also concerned about sourcing.

"When someone receives an approved prescription medication from a licensed Canadian pharmacy, there is an established regulatory and manufacturing framework behind that product. When someone purchases a vial labelled 'research use only' from an online source, I cannot automatically know that the concentration is accurate, that the product is sterile or even that the substance in the vial is what the label claims."

From this perspective, enthusiasm is not the enemy.

Premature certainty is.

The Physician Advocating for Peptide Research

Physician: "I agree that we cannot call investigational therapies proven. But absence of approval should not be interpreted as evidence that a molecule has no therapeutic potential."

This physician points out that modern medicine itself contains many successful peptide-based drugs. The biological mechanisms being explored are real, and some investigational peptides already have human pharmacology data.

"CJC-1295, for example, has been studied in humans and has demonstrated measurable effects on growth hormone and IGF-1. That does not prove every anti-aging claim being made online, but it does demonstrate that this is not imaginary biology." PubMed

The physician makes a broader argument about innovation.

"Every approved therapy was investigational at some point. If the medical community dismisses emerging compounds simply because they are early in development, we risk closing the door on potentially valuable treatments."

The appropriate response, this physician argues, should be better clinical research rather than dismissiveness.

"Where the early evidence is compelling, we should be asking how to study these compounds properly. We need standardized pharmaceutical products, appropriate dosing studies, randomized controlled trials and long-term safety data."

The Cautious Physician Responds

Physician: "I agree completely with studying them. What I disagree with is turning the research phase into the retail phase."

That may be the strongest distinction in the entire peptide debate.

Researching an investigational therapy and selling an investigational therapy to consumers as though its benefits are already established are fundamentally different activities.

The Peptide Advocate Responds

Physician: "And I would argue that regulators, researchers and industry need to move quickly enough to investigate compounds that patients are clearly interested in. Consumer demand is telling us something."

The physician argues that patients are increasingly interested in recovery, metabolic health, longevity and preserving function as they age. Instead of dismissing those goals, medicine should investigate them seriously.

But both physicians ultimately arrive at surprisingly similar ground.

The science deserves investigation.

The evidence needs to improve.

Quality matters.

Patients deserve accurate information.

And marketing should never outrun what the evidence can support.

Where I Stand on Peptides

My position sits somewhere between excitement and discipline.

I love this category.

I find the emerging science incredibly promising, and I believe we are probably at the beginning of a much larger era of peptide therapeutics.

But loving the science does not require pretending that every peptide being discussed online is ready for mainstream clinical use.

Actually, I think respecting the science requires the opposite.

BPC-157 deserves better human research precisely because the preclinical signals are interesting.

CJC-1295 deserves to be discussed according to what its human studies actually demonstrated, rather than being transformed into a cure-all for aging.

New metabolic peptides deserve rigorous clinical development because the success of existing peptide-based metabolic drugs has demonstrated how consequential this field can become.

There is room for optimism and skepticism at the same table.

That is how good science progresses.

Approved Does Not Mean Perfect, and Unapproved Does Not Mean Useless

There is another nuance worth addressing.

Regulatory approval does not mean a medication is risk-free. Approved medications have contraindications, side effects and uncertainties, and new safety information can emerge after approval.

Conversely, the fact that an investigational compound is not approved does not prove that it has no biological or therapeutic value.

What approval tells us is something different.

It tells us that a specific product has undergone a formal regulatory assessment for safety, efficacy and quality for particular conditions of use.

That is a much more meaningful distinction than simply labelling one side "good" and the other "bad."

The Wellness Industry Needs to Stop Selling Certainty

This may be my greatest concern about the current peptide conversation.

Wellness marketing is very good at turning possibilities into promises.

"May support" becomes "heals."

"Being investigated for" becomes "clinically proven."

Animal data becomes a human treatment claim.

A biological mechanism becomes an outcome.

That is where we lose credibility.

A clinic should be able to tell a patient, "This is interesting research, but we do not know yet."

There is tremendous integrity in that sentence.

Patients do not need us to make science sound more certain than it is.

They need us to help them understand the difference between what we know, what we suspect and what we are still trying to discover.

What Canadians Should Ask Before Considering Any Peptide

Before considering something marketed as peptide therapy, Canadians should first determine exactly what the product is and whether Health Canada has authorized that specific drug.

Authorized Canadian prescription drugs carry an eight-digit DIN. Health Canada also maintains a Drug Product Database that consumers and healthcare professionals can use to verify authorization. Recalls Canada

Patients should also ask what condition the drug is approved to treat, whether the proposed use is an approved indication, what human evidence supports the treatment, what the known risks are, where the product is being dispensed and who is medically responsible for monitoring treatment.

Those questions are not anti-innovation.

They are what informed healthcare decisions should look like.

What This Means for Canadian Wellness and Medical Aesthetic Clinics

The peptide conversation is particularly relevant to medical aesthetics, longevity and integrative wellness because the boundaries between these industries are becoming increasingly connected.

Patients who once entered a clinic primarily concerned about how they looked may now be asking about how they sleep, recover, maintain muscle, manage weight, preserve energy and age well.

That creates an enormous opportunity for clinics.

It also creates responsibility.

A clinic's credibility may increasingly depend on its willingness to distinguish between established medicine, off-label medicine, emerging research and unapproved therapy.

Being first is not always the same thing as being ahead.

Sometimes the strongest positioning a clinic can have is becoming the place where patients receive a thoughtful, evidence-informed explanation instead of another sales pitch.

The Future of Peptides May Be Much Bigger Than Today's Controversy

I do not believe the current controversy surrounding peptides means the category should be dismissed. I think it demonstrates exactly why the category deserves serious attention.

The success of established peptide-based medicines already tells us that peptides can become powerful therapeutic tools. Meanwhile, emerging compounds are giving researchers fascinating biological questions to investigate.

Some of today's experimental peptides may eventually fail. Some may prove useful only for narrow indications. Some may demonstrate risks that outweigh their benefits. And some may eventually become legitimate therapies that change the way we approach certain areas of medicine. That is how drug development works. We simply do not know which outcomes will occur yet.

For me, that uncertainty does not make the science less exciting. It makes the research more important.

I believe in being open to promising science without getting ahead of the science.

We should be curious enough to investigate these compounds, disciplined enough to demand good evidence and responsible enough to tell patients exactly where that evidence stands.

Because the future of peptide medicine will not ultimately be decided by TikTok, podcasts, wellness trends or marketing.

It will be decided by what rigorous human research eventually proves.

Copyright © Samantha Almas. All rights reserved.